Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation

Respiration

Volumn 93, Issue 3, 2017, Pages 212-225

  Frantzeskaki, Frantzeska ^a   Armaganidis, Apostolos ^a   Orfanos, Stylianos E ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acute respiratory distress syndrome; Coagulation; Immunothrombosis; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTITHROMBIN; CELL ADHESION MOLECULE; DROTRECOGIN; FIBRIN; GAMMA INTERFERON; HEPARIN; INTERLEUKIN 1; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SIVELESTAT; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR; CYTOKINE; PEPTIDE HYDROLASE;

ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD CLOTTING; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM CELL; EXTRACELLULAR TRAP; FIBRIN DEPOSITION; HUMAN; IMMUNOTHROMBOSIS; INFLAMMATION; LEUKOCYTE ACTIVATION; LUNG ALVEOLUS; LUNG CAPILLARY; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT OUTCOME; COMPLICATION; IMMUNOLOGY; LUNG; MEMBRANE MICROPARTICLE; NEUTROPHIL; VASCULARIZATION;

CELL-DERIVED MICROPARTICLES; CYTOKINES; ENDOTHELIAL CELLS; EXTRACELLULAR TRAPS; HUMANS; INFLAMMATION; LUNG; NEUTROPHILS; PEPTIDE HYDROLASES; PLATELET ACTIVATION; PULMONARY ALVEOLI; RESPIRATORY DISTRESS SYNDROME, ADULT; THROMBOSIS;

EID: 85008406322     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000453002     Document Type: Review

References (143)

1. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-2533.
2. Yadav H, Kor DJ: Platelets in the pathogenesis of acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2015;309: L915-L923.
3. Futier E, Pereira B, Jaber S: Intraoperative low-tidal-volume ventilation. N Engl J Med 2013;369:1862-1863.
4. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363:1107-1116.
5. Finigan JH: The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc Res 2009;77:35-38.
6. Sharp C, Millar AB, Medford AR: Advances in understanding of the pathogenesis of acute respiratory distress syndrome. Respiration 2015;89:420-434.
7. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 2013;369:2063.
8. Nagy Z, Kolev K, Csonka E, Pek M, Machovich R: Contraction of human brain endothelial cells induced by thrombogenic and fibrinolytic factors. An in vitro cell culture model. Stroke 1995;26:265-270.
9. Grinnell F, Feld M, Minter D: Fibroblast adhesion to fibrinogen and fibrin substrata: requirement for cold-insoluble globulin (plasma fibronectin). Cell 1980;19:517-525.
10. Shpacovitch V, Feld M, Hollenberg MD, Luger TA, Steinhoff M: Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol 2008;83:1309-1322.
11. van der Poll T, Herwald H: The coagulation system and its function in early immune defense. Thromb Haemost 2014;112:640-648.
12. Engelmann B, Massberg S: Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13:34-45.
13. Han S, Mallampalli RK: The acute respiratory distress syndrome: from mechanism to translation. J Immunol 2015;194:855-860.
14. Grailer JJ, Canning BA, Kalbitz M, Haggadone MD, Dhond RM, Andjelkovic AV, et al. Critical role for the NLRP3 inflammasome during acute lung injury. J Immunol 2014;192:5974-5983.
15. Dolinay T, Kim YS, Howrylak J, Hunninghake GM, An CH, Fredenburgh L, et al. Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med 2012;185:1225-1234.
16. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010;464:104-107.
17. Ray NB, Durairaj L, Chen BB, McVerry BJ, Ryan AJ, Donahoe M, et al. Dynamic regulation of cardiolipin by the lipid pump Atp8b1 determines the severity of lung injury in experimental pneumonia. Nat Med 2010;16:1120-1127.
18. Sun S, Sursal T, Adibnia Y, Zhao C, Zheng Y, Li H, et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS One 2013;8:e59989.
19. de Stoppelaar SF, van 't Veer C, van der Poll T: The role of platelets in sepsis. Thromb Haemost 2014;112:666-677.
20. Maniatis NA, Kotanidou A, Catravas JD, Orfanos SE: Endothelial pathomechanisms in acute lung injury. Vasc Pharmacol 2008;49:119-133.
21. Levi M, van der Poll T, ten Cate H: Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006;32:33-39.
22. DelGiudice LA, White GA: The role of tissue factor and tissue factor pathway inhibitor in health and disease states. J Vet Emerg Crit Care (San Antonio) 2009;19:23-29.
23. Sebag SC, Bastarache JA, Ware LB: Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr Pharm Biotechnol 2011;12:1481-1496.
24. Kirschenbaum LA, McKevitt D, Rullan M, Reisbeck B, Fujii T, Astiz ME: Importance of platelets and fibrinogen in neutrophil-endothelial cell interactions in septic shock. Crit Care Med 2004;32:1904-1909.
25. Tomashefski JF Jr, Davies P, Boggis C, Greene R, Zapol WM, Reid LM: The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983;112:112-126.
26. Vesconi S, Rossi GP, Pesenti A, Fumagalli R, Gattinoni L: Pulmonary microthrombosis in severe adult respiratory distress syndrome. Crit Care Med 1988;16:111-113.
27. Greene R, Zapol WM, Snider MT, Reid L, Snow R, O'Connell RS, et al. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis 1981;124:593-601.
28. Greene R, Lind S, Jantsch H, Wilson R, Lynch K, Jones R, et al. Pulmonary vascular obstruction in severe ARDS: angiographic alterations after i.v. fibrinolytic therapy. Am J Roentgenol 1987;148:501-508.
29. Lim MY, Ataga KI, Key NS: Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol 2013;20:472-477.
30. Pfeiler S, Massberg S, Engelmann B: Biological basis and pathological relevance of microvascular thrombosis. Thromb Res 2014;133(suppl 1):S35-S37.
31. Saldeen T: Intravascular coagulation in the lungs in experimental fat embolism. Acta Chir Scand 1969;135:653-662.
32. Bone RC, Francis PB, Pierce AK: Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 1976;61:585-589.
33. Taylor FB Jr: Response of anticoagulant pathways in disseminated intravascular coagulation. Semin Thromb Hemost 2001;27:619-631.
34. Griffin JH, Fernandez JA, Gale AJ, Mosnier LO: Activated protein C. J Thromb Haemost 2007;5(suppl 1):73-80.
35. Isshiki T, Sakamoto S, Kinoshita A, Sugino K, Kurosaki A, Homma S: Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration 2015;89:201-207.
36. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
37. Jiang JS, Chou HC, Wang LF, Lang YD, Chen CM: Effects of activated protein C on ventilator-induced lung injury in rats. Respiration 2010;80:246-253.
38. Ware LB, Fang X, Matthay MA: Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:L514-L521.
39. Gando S, Otomo Y: Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care (London) 2015;19:72.
40. Thomas GM, Carbo C, Curtis BR, Martinod K, Mazo IB, Schatzberg D, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood 2012;119:6335-6343.
41. Alvarez P, Carrasco R, Romero-Dapueto C, Castillo RL: Transfusion-related acute lung injured (TRALI): current concepts. Open Respir Med J 2015;9:92-96.
42. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004;59:130-135.
43. Choi G, Wolthuis EK, Bresser P, Levi M, van der Poll T, Dzoljic M, et al. Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology 2006;105:689-695.
44. Haitsma JJ, Schultz MJ, Hofstra JJ, Kuiper JW, Juco J, Vaschetto R, et al. Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia. Eur Respir J 2008;32:1599-1606.
45. Schultz MJ, Determann RM, Royakkers AA, Wolthuis EK, Korevaar JC, Levi MM: Bronchoalveolar activation of coagulation and inhibition of fibrinolysis during ventilator-associated lung injury. Crit Care Res Pract 2012;2012:961784.
46. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD: Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007;35:1821-1828.
47. Milsom C, Rak J: Tissue factor and cancer. Pathophysiol Haemost Thromb 2008;36:160-176.
48. Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, et al. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 2002;168:3577-3585.
49. Ruf W: New players in the sepsis-protective activated protein C pathway. J Clin Invest 2010;120:3084-3087.
50. Wygrecka M, Jablonska E, Guenther A, Preissner KT, Markart P: Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost 2008;99:494-501.
51. Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, et al. Induction of microparticle-and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004;103:4545-4553.
52. Bastarache JA, Wang L, Geiser T, Wang Z, Albertine KH, Matthay MA, et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007;62:608-616.
53. Sabharwal AK, Bajaj SP, Ameri A, Tricomi SM, Hyers TM, Dahms TE, et al. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med 1995;151:758-767.
54. Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, Ware LB: Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 2008;294:L874-L881.
55. Assinger A, Laky M, Schabbauer G, Hirschl AM, Buchberger E, Binder BR, et al. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. J Thromb Haemost 2011;9:799-809.
56. Tsirigotis P, Chondropoulos S, Frantzeskaki F, Stamouli M, Gkirkas K, Bartzeliotou A, et al. Thrombocytopenia in critically ill patients with severe sepsis/septic shock: prognostic value and association with a distinct serum cytokine profile. J Crit Care 2016;32:9-15.
57. Douda DN, Jackson R, Grasemann H, Palaniyar N: Innate immune collectin surfactant protein D simultaneously binds both neutrophil extracellular traps and carbohydrate ligands and promotes bacterial trapping. J Immunol 2011;187:1856-1865.
58. Kor DJ, Talmor DS, Banner-Goodspeed VM, Carter RE, Hinds R, Park PK, et al. Lung Injury Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open 2012;2:e001606.
59. McVey M, Tabuchi A, Kuebler WM: Microparticles and acute lung injury. Am J Physiol Lung Cell Mol Physiol 2012;303:L364-L381.
60. Wijten P, van Holten T, Woo LL, Bleijerveld OB, Roest M, Heck AJ, et al. High precision platelet releasate definition by quantitative reversed protein profiling-brief report. Arterioscler Thromb Vasc Biol 2013;33:1635-1638.
61. Puneet P, Moochhala S, Bhatia M: Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2005;288:L3-L15.
62. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR: Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896-899.
63. Boman HG: Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995;13:61-92.
64. Kraemer BF, Campbell RA, Schwertz H, Cody MJ, Franks Z, Tolley ND, et al. Novel anti-bacterial activities of beta-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathogens 2011;7:e1002355.
65. Freishtat RJ, Natale J, Benton AS, Cohen J, Sharron M, Wiles AA, et al. Sepsis alters the megakaryocyte-platelet transcriptional axis resulting in granzyme B-mediated lymphotoxicity. Am J Respir Crit Care Med 2009;179:467-473.
66. Yaguchi A, Lobo FL, Vincent JL, Pradier O: Platelet function in sepsis. J Thromb Haemost 2004;2:2096-2102.
67. Hu JY, Li CL, Wang YW: Altered proteomic pattern in platelets of rats with sepsis. Blood Cells Mol Dis 2012;48:30-35.
68. Etulain J, Negrotto S, Carestia A, Pozner RG, Romaniuk MA, D'Atri LP, et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thromb Haemost 2012;107:99-110.
69. Katz JN, Kolappa KP, Becker RC: Beyond thrombosis: the versatile platelet in critical illness. Chest 2011;139:658-668.
70. Idell S, Maunder R, Fein AM, Switalska HI, Tuszynski GP, McLarty J, et al. Platelet-specific alpha-granule proteins and thrombospondin in bronchoalveolar lavage in the adult respiratory distress syndrome. Chest 1989;96:1125-1132.
71. Levy BD, Serhan CN: Resolution of acute inflammation in the lung. Annu Rev Physiol 2014;76:467-492.
72. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 2002;13:2497-2507.
73. Dudek SM, Jacobson JR, Chiang ET, Birukov KG, Wang P, Zhan X, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem 2004;279:24692-24700.
74. Zarbock A, Singbartl K, Ley K: Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006;116:3211-3219.
75. Hammer DA, Apte SM: Simulation of cell rolling and adhesion on surfaces in shear flow: general results and analysis of selectin-mediated neutrophil adhesion. Biophys J 1992;63:35-57.
76. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 2012;122:2661-2671.
77. Peters MJ, Dixon G, Kotowicz KT, Hatch DJ, Heyderman RS, Klein NJ: Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J Haematol 1999;106:391-399.
78. Weber B, Schuster S, Zysset D, Rihs S, Dickgreber N, Schurch C, et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS Pathogens 2014;10:e1003900.
79. Grommes J, Alard JE, Drechsler M, Wantha S, Morgelin M, Kuebler WM, et al. Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. Am J Respir Crit Care Med 2012;185:628-636.
80. Williams AE, Chambers RC: The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol 2014;306:L217-L230.
81. Asaduzzaman M, Lavasani S, Rahman M, Zhang S, Braun OO, Jeppsson B, et al. Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. Crit Care Med 2009;37:1389-1396.
82. Carvalho AC, Quinn DA, DeMarinis SM, Beitz JG, Zapol WM: Platelet function in acute respiratory failure. Am J Hematol 1987;25:377-388.
83. Meyer NJ, Feng R, Li M, Zhao Y, Sheu CC, Tejera P, et al. IL1RN coding variant is associated with lower risk of acute respiratory distress syndrome and increased plasma IL-1 receptor antagonist. Am J Respir Crit Care Med 2013;187:950-959.
84. Madach K, Aladzsity I, Szilagyi A, Fust G, Gal J, Penzes I, et al. 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Crit Care (London) 2010;14:R79.
85. Zawrotniak M, Rapala-Kozik M: Neutrophil extracellular traps (NETs)-formation and implications. Acta Biochim Pol 2013;60:277-284.
86. Kaplan MJ, Radic M: Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012;189:2689-2695.
87. Oehmcke S, Morgelin M, Herwald H: Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 2009;1:225-230.
88. von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012;209:819-835.
89. Kambas K, Mitroulis I, Ritis K: The emerging role of neutrophils in thrombosis-the journey of TF through NETs. Front Immunol 2012;3:385.
90. Kambas K, Mitroulis I, Apostolidou E, Girod A, Chrysanthopoulou A, Pneumatikos I, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One 2012;7:e45427.
91. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012;10:136-144.
92. Fuchs TA, Brill A, Wagner DD: Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012;32:1777-1783.
93. Kolaczkowska E, Kubes P: Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013;13:159-175.
94. Steppich BA, Seitz I, Busch G, Stein A, Ott I: Modulation of tissue factor and tissue factor pathway inhibitor-1 by neutrophil proteases. Thromb Haemost 2008;100:1068-1075.
95. Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 2012;7:e32366.
96. Nishinaka Y, Arai T, Adachi S, Takaori-Kondo A, Yamashita K: Singlet oxygen is essential for neutrophil extracellular trap formation. Biochem Biophys Res Commun 2011;413:75-79.
97. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009;15:1318-1321.
98. Urban CF, Reichard U, Brinkmann V, Zychlinsky A: Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell Microbiol 2006;8:668-676.
99. Wildhagen KC, Garcia de Frutos P, Reutelingsperger CP, Schrijver R, Areste C, Ortega-Gomez A, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood 2014;123:1098-1101.
100. Lam FW, Cruz MA, Leung HC, Parikh KS, Smith CW, Rumbaut RE: Histone induced platelet aggregation is inhibited by normal albumin. Thromb Res 2013;132:69-76.
101. Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, Choi G, et al. Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 2010;23:105-111.
102. Tasaki O, Mozingo DW, Dubick MA, Goodwin CW, Yantis LD, Pruitt BA Jr: Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model. Crit Care Med 2002;30:637-643.
103. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD: Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care (London) 2010;14:445.
104. Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM: Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 2009;30:249-256.
105. Brinkmann V, Zychlinsky A: Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007;5:577-582.
106. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA: Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009;119:3450-3461.
107. Li X, Li C, Liang W, Bi Y, Chen M, Dong S: Protectin D1 promotes resolution of inflammation in a murine model of lipopolysaccharide-induced acute lung injury via enhancing neutrophil apoptosis. Chin Med J 2014;127:810-814.
108. Mause SF, Weber C: Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010;107:1047-1057.
109. Owens AP 3rd, Mackman N: Microparticles in hemostasis and thrombosis. Circ Res 2011;108:1284-1297.
110. Brown GT, McIntyre TM: Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1beta-rich microparticles. J Immunol 2011;186:5489-5496.
111. Barry OP, Pratico D, Lawson JA, FitzGerald GA: Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997;99:2118-2127.
112. Jy W, Ricci M, Shariatmadar S, Gomez-Marin O, Horstman LH, Ahn YS: Microparticles in stored red blood cells as potential mediators of transfusion complications. Transfusion 2011;51:886-893.
113. Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, et al. "Role reversal" for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007;8:1303-1312.
114. Lechner D, Weltermann A: Circulating tissue factor-exposing microparticles. Thromb Res 2008;122(suppl 1):S47-S54.
115. Bastarache JA, Fremont RD, Kropski JA, Bossert FR, Ware LB: Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2009;297: L1035-L1041.
116. Rosing J, Speijer H, Zwaal RF: Prothrombin activation on phospholipid membranes with positive electrostatic potential. Biochemistry 1988;27:8-11.
117. Morel O, Jesel L, Freyssinet JM, Toti F: Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011;31:15-26.
118. Guervilly C, Lacroix R, Forel JM, Roch A, Camoin-Jau L, Papazian L, et al. High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. Crit Care (London) 2011;15:R31.
119. El Kebir D, Jozsef L, Pan W, Wang L, Petasis NA, Serhan CN, et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med 2009;180:311-319.
120. Morel O, Toti F, Morel N, Freyssinet JM: Microparticles in endothelial cell and vascular homeostasis: are they really noxious? Haematologica 2009;94:313-317.
121. Mostefai HA, Agouni A, Carusio N, Mastronardi ML, Heymes C, Henrion D, et al. Phosphatidylinositol 3-kinase and xanthine oxidase regulate nitric oxide and reactive oxygen species productions by apoptotic lymphocyte microparticles in endothelial cells. J Immunol 2008;180:5028-5035.
122. Rothmeier AS, Ruf W: Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol 2012;34:133-149.
123. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008;178:618-623.
124. Allingstrup M, Wetterslev J, Ravn FB, Moller AM, Afshari A: Antithrombin III for critically ill patients. Cochrane Database Syst Rev 2016;2:CD005370.
125. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247.
126. Miyoshi S, Ito R, Katayama H, Dote K, Aibiki M, Hamada H, et al. Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. Drug Design Dev Ther 2014;8:1211-1219.
127. Kotanidou A, Loutrari H, Papadomichelakis E, Glynos C, Magkou C, Armaganidis A, et al. Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vasc Pharmacol 2006;45:134-140.
128. Rehberg S, Yamamoto Y, Sousse LE, Jonkam C, Cox RA, Prough DS, et al. Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome. J Trauma Acute Care Surg 2014;76:126-133.
129. Claria J, Serhan CN: Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995;92:9475-9479.
130. Taylor FB, Coller BS, Chang AC, Peer G, Jordan R, Engellener W, et al. 7E3 F(ab′)2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Blood 1997;89:4078-4084.
131. Chen W, Janz DR, Bastarache JA, May AK, O'Neal HR Jr, Bernard GR, et al. Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. Crit Care Med 2015;43:801-807.
132. Kor DJ, Erlich J, Gong MN, Malinchoc M, Carter RE, Gajic O, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 2011;39:2393-2400.
133. Boyle AJ, Di Gangi S, Hamid UI, Mottram LJ, McNamee L, White G, et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care (London) 2015;19:109.
134. O'Neal HR Jr, Koyama T, Koehler EA, Siew E, Curtis BR, Fremont RD, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 2011;39:1343-1350.
135. Mazzeffi M, Kassa W, Gammie J, Tanaka K, Roman P, Zhan M, et al. Preoperative aspirin use and lung injury after aortic valve replacement surgery: a retrospective cohort study. Anesthesia Analgesia 2015;121:271-277.
136. Kor DJ, Carter RE, Park PK, Festic E, Banner-Goodspeed VM, Hinds R, et al. Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial. JAMA 2016;315:2406-2414.
137. Cardenes N, Caceres E, Romagnoli M, Rojas M: Mesenchymal stem cells: a promising therapy for the acute respiratory distress syndrome. Respiration 2013;85:267-278.
138. Masterson C, Jerkic M, Curley GF, Laffey JG: Mesenchymal stromal cell therapies: potential and pitfalls for ARDS. Minerva Anestesiol 2015;81:179-194.
139. Trounson A, Thakar RG, Lomax G, Gibbons D: Clinical trials for stem cell therapies. BMC Med 2011;9:52.
140. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP: A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013;143:1590-1598.
141. Johnston LK, Rims CR, Gill SE, McGuire JK, Manicone AM: Pulmonary macrophage subpopulations in the induction and resolution of acute lung injury. Am J Respir Cell Mol Biol 2012;47:417-426.
142. Gatti S, Bruno S, Deregibus MC, Sordi A, Cantaluppi V, Tetta C, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 2011;26:1474-1483.
143. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012;18:759-765.